BiotechTube
Home/TheraVac Biologics/Mark Lievonen, CM, FCPA, FCA
ML

Mark Lievonen, CM, FCPA, FCA

Business Advisor

TheraVac Biologics

Therapeutic Areas

Alzheimer's DiseaseFrontotemporal DementiaMultiple SclerosisTraumatic Brain InjuryNeurodegenerative Diseases

TheraVac Biologics Pipeline

DrugIndicationPhase
TV-301Alzheimer's disease (prodromal to mild)Preclinical
TV-202Frontotemporal dementiaPreclinical
TV-100TBDPreclinical

Leadership Team at TheraVac Biologics

AR
Ali Riazi, PhD
Co-founder and CEO
LB
Laurent Balenci, PhD, MBA
Co-founder and COO
KB
Kiran Bhaskar, PhD
Scientific Co-founder
BC
Bryce Chackerian, PhD
Scientific Co-founder
View full TheraVac Biologics profile